Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
Last Updated: Monday, October 3, 2022
Data from the largest real-world study of MPN patients younger than age 25 at diagnosis provided unique insight about this patient population, including ET being the most common subtype (71.6%); higher than expected rates of thrombosis, hemorrhage, and transformation, compared with reported literature; and that contemporary scores were not able to predict survival for young patients with ET or PV.
Advertisement
News & Literature Highlights
